Check-Cap Ltd logo

Check-Cap Ltd

NEW
STU:7CC (Israel)  
€ 1.03 (-3.74%) Oct 30
At Loss
P/B:
0.28
Market Cap:
€ 6.16M ($ 6.70M)
Enterprise V:
€ -16.72M ($ -18.18M)
Volume:
-
Avg Vol (2M):
1.50K
Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Check-Cap Ltd ( STU:7CC ) from 2017 to Oct 31 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Check-Cap stock (STU:7CC) PE ratio as of Oct 31 2024 is 0. More Details

Check-Cap Ltd (STU:7CC) PE Ratio (TTM) Chart

To

Check-Cap Ltd (STU:7CC) PE Ratio (TTM) Historical Data

Total 1247
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Check-Cap PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-10-31 At Loss 2024-08-29 At Loss
2024-10-30 At Loss 2024-08-28 At Loss
2024-10-29 At Loss 2024-08-27 At Loss
2024-10-28 At Loss 2024-08-26 At Loss
2024-10-25 At Loss 2024-08-23 At Loss
2024-10-24 At Loss 2024-08-22 At Loss
2024-10-23 At Loss 2024-08-21 At Loss
2024-10-22 At Loss 2024-08-20 At Loss
2024-10-21 At Loss 2024-08-19 At Loss
2024-10-18 At Loss 2024-08-16 At Loss
2024-10-17 At Loss 2024-08-15 At Loss
2024-10-16 At Loss 2024-08-14 At Loss
2024-10-15 At Loss 2024-08-13 At Loss
2024-10-14 At Loss 2024-08-12 At Loss
2024-10-11 At Loss 2024-08-09 At Loss
2024-10-10 At Loss 2024-08-08 At Loss
2024-10-09 At Loss 2024-08-07 At Loss
2024-10-08 At Loss 2024-08-06 At Loss
2024-10-07 At Loss 2024-08-05 At Loss
2024-10-04 At Loss 2024-08-02 At Loss
2024-10-03 At Loss 2024-08-01 At Loss
2024-10-02 At Loss 2024-07-31 At Loss
2024-10-01 At Loss 2024-07-30 At Loss
2024-09-30 At Loss 2024-07-29 At Loss
2024-09-27 At Loss 2024-07-26 At Loss
2024-09-26 At Loss 2024-07-25 At Loss
2024-09-25 At Loss 2024-07-24 At Loss
2024-09-24 At Loss 2024-07-23 At Loss
2024-09-23 At Loss 2024-07-22 At Loss
2024-09-20 At Loss 2024-07-19 At Loss
2024-09-19 At Loss 2024-07-18 At Loss
2024-09-18 At Loss 2024-07-17 At Loss
2024-09-17 At Loss 2024-07-16 At Loss
2024-09-16 At Loss 2024-07-15 At Loss
2024-09-13 At Loss 2024-07-12 At Loss
2024-09-12 At Loss 2024-07-11 At Loss
2024-09-11 At Loss 2024-07-10 At Loss
2024-09-10 At Loss 2024-07-09 At Loss
2024-09-09 At Loss 2024-07-08 At Loss
2024-09-06 At Loss 2024-07-05 At Loss
2024-09-05 At Loss 2024-07-04 At Loss
2024-09-04 At Loss 2024-07-03 At Loss
2024-09-03 At Loss 2024-07-02 At Loss
2024-09-02 At Loss 2024-07-01 At Loss
2024-08-30 At Loss 2024-06-28 At Loss

Check-Cap Ltd (STU:7CC) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.